Certain genes have the potential to mutate into oncogenes, which can drive the development of cancer by promoting uncontrolled cell proliferation and blocking the normal process of apoptosis (cell death). For years, cancer treatments have focused on shutting down these rogue genes and the proteins they produce. However, a new study from researchers at Stanford University takes a completely different approach—one that aims to harness the power of oncogenes to treat cancer.
“Since oncogenes were discovered, people have been trying to shut them down in cancer,” said Roman Sarott, co-first author of the study. “Instead, we’re trying to use them to turn signaling on that, we hope, will prove beneficial for treatment.” This innovative strategy targets a specific oncogene protein called BCL6, which is known to play a key role in diffuse large B-cell lymphoma (DLBCL), a type of blood cancer. In its mutated form, BCL6 binds to DNA near genes that would normally trigger apoptosis, effectively turning them off and allowing cancer cells to continue dividing uncontrollably.
Continue reading… “Stanford Researchers Turn Oncogenes Into Cancer-Killing Signals in Revolutionary New Approach”